Trevi Therapeutics Inc. (TRVI)
6.35
0.08 (1.28%)
At close: Apr 24, 2025, 3:59 PM
6.20
-2.36%
After-hours: Apr 24, 2025, 06:14 PM EDT
1.28% (1D)
| Bid | 6.2 |
| Market Cap | 613.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.91M |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | -13.51 |
| Forward PE | -10.29 |
| Analyst | Buy |
| Ask | 6.45 |
| Volume | 725,643 |
| Avg. Volume (20D) | 2,199,386 |
| Open | 6.25 |
| Previous Close | 6.27 |
| Day's Range | 6.18 - 6.38 |
| 52-Week Range | 2.30 - 7.39 |
| Beta | 0.41 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 26
Stock Exchange NASDAQ
Ticker Symbol TRVI
Analyst Forecast
According to 9 analyst ratings, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 214.96% from the latest price.
Stock Forecasts1 month ago
+41.16%
Trevi Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+15.83%
Trevi Therapeutics shares are trading higher after HC Wainwright & Co. reiterated a Buy rating on the stock and raised its price target from $6 to $7.5.
